script.reportAU
Ophthalmology

Aciclovir

Brand: Xorox

PBAC's latest decision on Aciclovir: Not recommended (2021). Considered for Treatment of Herpes simplex keratitis (HSK).

PBAC outcome
Not recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2015
Submissions
3
2015 → 2021

Eligible population

Patients with Herpes simplex keratitis requiring topical aciclovir 3% eye ointment.

Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
AciVision
Economic model
Cost-minimisation
ICER note
This is a minor submission for a generic brand of an existing PBS-listed medicine; no economic evaluation or ICER was modelled.

Why PBAC said no

Reasons cited in the latest PSD: Inadequate basis for the requested AEMP (higher than the delisted Zovirax and currently listed AciVision); no evidence of significant improvement in efficacy or reduction of toxicity over the alternative therapy (AciVision)

Submission history

Similar precedents

Open on full dashboard →